Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Ordinary Shares, no par value
-
Shares outstanding
-
3,838,602,439
-
Total 13F shares
-
477,583
-
Share change
-
+233,773
-
Total reported value
-
$1,060,150
-
Price per share
-
$2.22
-
Number of holders
-
8
-
Value change
-
+$519,387
-
Number of buys
-
4
-
Number of sells
-
2
Institutional Holders of Can-Fite BioPharma Ltd. - Ordinary Shares, no par value (CANF) as of Q1 2024
As of 31 Mar 2024,
Can-Fite BioPharma Ltd. - Ordinary Shares, no par value (CANF) was held by
8 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
477,583 shares.
The largest 8 holders included
ARMISTICE CAPITAL, LLC, MORGAN STANLEY, RHUMBLINE ADVISERS, CITADEL ADVISORS LLC, FIFTH THIRD BANCORP, UBS Group AG, NATIONAL BANK OF CANADA /FI/, and CITIGROUP INC.
This page lists
8
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.